Variables | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95%CI | P | HR | 95%CI | P | |
MSK GI cohorta | ||||||
DDR mutations (≥ 2 vs. < 2) | 0.32 | 0.17–0.58 | < 0.001 | 0.32 | 0.17–0.60 | < 0.001 |
TMB (high vs. low) | 0.38 | 0.22–0.66 | < 0.001 | 0.41 | 0.24–0.73 | < 0.002 |
Janjigian cohortb | ||||||
DDR mutations (≥ 2 vs. < 2) | 0.30 | 0.10–0.88 | 0.029 | 0.22 | 0.07–0.71 | 0.012 |
TMB (high vs. low) | 0.38 | 0.14–1.00 | 0.053 | 0.21 | 0.07–0.64 | 0.006 |
PD-L1 (positive vs. negative) | 0.24 | 0.08–0.77 | 0.016 | 0.09 | 0.02–0.51 | 0.006 |
PUCH cohortc | ||||||
DDR mutations (≥ 2 vs. < 2) | 0.22 | 0.05–0.95 | 0.042 | 0.14 | 0.03–0.64 | 0.011 |
TMB (high vs. low) | 0.35 | 0.14–0.89 | 0.027 | 0.23 | 0.09–0.63 | 0.004 |
PD-L1 (positive vs. negative) | 0.85 | 0.37–1.90 | 0.696 | 0.90 | 0.39–2.10 | 0.809 |
aThe multivariate analysis in the MSK-GI cohort was adjusted for age, gender, cancer type, drug, and metastasis. bThe multivariate analysis in the Janjigian cohort was adjusted for age, gender, HER2 and liver metastasis. cThe multivariate analysis in the PUCH cohort was adjusted for age, gender, immunotherapy and primary tumor.